Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 15/20 | 0.56 |
| ▸ | ADRB3 | P13945 | 10/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 8/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22481225 | 0.87 | ADRB2 (0.56) | ADRB2ADRB3ADRB1DRD2ADRA1A | |
| SCHEMBL22480917 | 0.81 | ADRB2 (0.56) | ADRB2ADRB3ADRB1DRD2ADRA1A | |
| SCHEMBL22481288 | 0.81 | ADRB2 (0.56) | ADRB2ADRB3ADRB1DRD2SLC2A1 | |
| SCHEMBL22480918 | 0.78 | MEN1 (0.52) | ADRB2ADRB3SLC2A1 | |
| SCHEMBL22481217 | 0.77 | ADRB2 (0.57) | ADRB2ADRB3ADRB1DRD2ADRA1A | |
| SCHEMBL11089904 | 0.77 | ADRB2 (0.59) | ADRB2ADRB3ADRB1DRD2SLC2A1 | |
| Hydrochloric Acid SCHEMBL11093309 | 0.76 | ADRB2 (0.58) | ADRB2ADRB3ADRB1DRD2SLC2A1 | |
| SCHEMBL22481289 | 0.75 | ADRB2 (0.63) | ADRB2ADRB3ADRB1DRD2SLC2A1 | |
| SCHEMBL7151096 | 0.75 | SLC2A1 (0.83) | ADRB2ADRB3ADRB1SLC2A1ADRA1A | |
| SCHEMBL7151100 | 0.75 | SLC2A1 (0.83) | ADRB2ADRB3ADRB1SLC2A1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263749-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | CURASEN THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230263749-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | CURASEN THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20210371380-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2021-12-02 | — | — | US | disclosed |
| US-11040944-B2 | Beta adrenergic agonist and methods of using the same | CURASEN THERAPEUTICS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-10947196-B2 | Beta adrenergic agonist and methods of using the same | CURASEN THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200308115-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308115-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB3 4/4885ADRB1 2/4885 |
| US-10947196-B2 | Beta adrenergic agonist and methods of using the same | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB3 4/4885ADRB1 2/4885 |
| US-20210371380-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB3 4/4885ADRB1 2/4885 |
| US-11040944-B2 | Beta adrenergic agonist and methods of using the same | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB3 4/4885ADRB1 2/4885 |
| US-20230263749-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | ADRA2A, SNCA, ADRA1A | ADRB2 4/4885ADRB3 8/4885ADRB1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.